Plasma calcitonin and tumors.

Area of Science:

• Oncology
• Biochemistry
• Clinical Diagnostics

Background:

• Cancer patients often exhibit altered levels of specific biomarkers.
• Investigating novel or underutilized tumor markers is crucial for early cancer detection and management.

Purpose of the Study:

• To evaluate the diagnostic utility of plasma immunoreactive calcitonin (iCT) and carcinoembryonic antigen (CEA) in various cancers.
• To assess the incidence of hypercalcemia and parathyroid hormone (iPTH) levels in cancer patients.

Main Methods:

• Plasma levels of calcium, phosphorus, iCT, iPTH, and CEA were measured.
• Patients with breast, lung, kidney, gastrointestinal, and other tumors were included.

Main Results:

• Elevated iCT was observed in a high percentage of patients across different cancer types (e.g., 65.3% in renal cancer, 53.6% in lung cancer).
• Hypercalcemia was noted in some lung cancer patients, with corresponding iCT elevation.
• iPTH levels were rarely elevated, indicating infrequent primary or ectopic hyperparathyroidism.

Conclusions:

• Plasma iCT is a promising tumor marker for a broad range of cancers.
• Combined measurement of iCT and CEA enhances diagnostic accuracy for cancer.
• Ectopic or primary hyperparathyroidism is uncommon in this cancer patient cohort.